61 Cu-NODAGA Prostate-specific Membrane Antigen Imaging and Therapy for Prostate Cancer: Phase 1 Trial of a New Class of 61 Cu-labeled PET Radiotracers

Key Points

• Cu-NODAGA PSMA imaging demonstrates safety and effectiveness for prostate cancer treatment.
• The trial supports the use of innovative Cu-labeled PET radiotracers in oncology.
• Analysis of copper-based radiotracers coupled with prostate-specific treatment raises new therapeutic opportunities.
• Further exploration is essential to maximize the potential of these novel radiotracers for other malignancies.